Annual report [Section 13 and 15(d), not S-K Item 405]

Segment information

v3.26.1
Segment information
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment information

12. Segment information

 

The Company operates and manages its business as one reportable and operating segment dedicated to the research and development Company’s novel orally administered antiviral influenza candidate. The measure of segment assets is reported on the balance sheet as total consolidated assets. In addition, the Company manages the business activities on a consolidated basis.

 

The Company’s CODM reviews financial information presented on a consolidated basis and decides how to allocate resources based on net income (loss).

 

Significant segment expenses include research and development, salaries, insurance, and stock-based compensation. Operating expenses include all remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM (table in thousands):

 

    2025     2024  
    Year ended December 31,  
    2025     2024  
Revenue   $ -     $ -  
                 
Less:                
Research and development     4,081       10,785  
Salaries and personnel costs     1,573       2,900  
Insurance     241       286  
Stock-based compensation     270       643  
Other operating expenses     2,854       3,264  
Other income     (188 )     (374 )
Net loss   $ (8,831 )   $ (17,504 )